Exane Derivatives’s Biogen BIIB Stock Holding History

Exane Derivatives’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$204	Hold	1	–	–	﹤0.01%	675
2022 Q1	$211	Hold	1	–	–	﹤0.01%	962
2021 Q4	$240	Sell	1 -369	-100%	-$94.9K	﹤0.01%	828
2021 Q3	$105K	Buy	370 +369	+36,900%	+$121K	0.03%	518
2021 Q2	$352	Sell	1 -9	-90%	-$2.73K	﹤0.01%	979
2021 Q1	$2.8K	Hold	10	–	–	﹤0.01%	658
2020 Q4	$2.45K	Hold	10	–	–	﹤0.01%	607
2020 Q3	$2.84K	Sell	10 -1,415	-99%	-$395K	﹤0.01%	544
2020 Q2	$381K	Buy	1,425 +1,412	+10,862%	+$424K	0.1%	173
2020 Q1	$4.11K	Hold	13	–	–	﹤0.01%	461
2019 Q4	$3.81K	Sell	13 -1,486	-99%	-$412K	﹤0.01%	454
2019 Q3	$349K	Hold	1,499	–	–	0.06%	191
2019 Q2	$350K	Sell	1,499 -998	-40%	-$230K	0.06%	207
2019 Q1	$590K	Buy	2,497 +2,189	+711%	+$689K	0.12%	142
2018 Q4	$92.7K	Buy	308 +135	+78%	+$43.1K	0.02%	325
2018 Q3	$61.4K	Sell	173 -302	-64%	-$104K	0.01%	362
2018 Q2	$139K	Sell	475 -1,560	-77%	-$439K	0.02%	293
2018 Q1	$549K	Buy	2,035 +1,293	+174%	+$401K	0.11%	160
2017 Q4	$236K	Buy	742 +32	+5%	+$10.3K	0.04%	228
2017 Q3	$222K	Buy	710 +632	+810%	+$187K	0.04%	194
2017 Q2	$21.2K	Sell	78 -6	-7%	-$1.59K	﹤0.01%	364
2017 Q1	$23K	Sell	84 -91	-52%	-$25.7K	0.01%	318
2016 Q4	$49.6K	Sell	175 -8,420	-98%	-$2.5M	0.01%	299
2016 Q3	$2.69M	Buy	8,595 +8,314	+2,959%	+$2.46M	0.4%	59
2016 Q2	$67.9K	Buy	281 +9	+3%	+$2.37K	0.01%	262
2016 Q1	$70.8K	Sell	272 -212	-44%	-$56K	0.01%	272
2015 Q4	$148K	Buy	484 +168	+53%	+$48.3K	0.02%	177
2015 Q3	$92.2K	Buy	316 +266	+532%	+$87.8K	0.01%	237
2015 Q2	$20.2K	Hold	50	–	–	﹤0.01%	343
2015 Q1	$21.1K	Sell	50 -200	-80%	-$78.8K	﹤0.01%	358
2014 Q4	$84.9K	Buy	+250	New	+$80.9K	0.01%	297

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Exane Derivatives's BIIB Position: Q2 2022 in Review

Exane Derivatives held its Biogen (BIIB) position steady in Q2 2022 at 1 share worth $204. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Exane Derivatives first reported a position in BIIB in Q4 2014 and has held it in 31 quarters since. The position peaked at $2.69M in Q3 2016. 928 funds tracked by Wall St. Rank hold BIIB as of Q2 2022.

Exane Derivatives held 1 share of Biogen worth $204 as of Q2 2022.
Exane Derivatives left its Biogen share count unchanged in Q2 2022.
Biogen made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #675 holding.
Exane Derivatives first reported a position in Biogen in Q4 2014 and has held it in 31 quarters since.
Exane Derivatives's Biogen position peaked at $2.69M in Q3 2016.
928 funds tracked by Wall St. Rank held Biogen as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.